Abstract
Barrett esophagus (BE) is defined by the presence of intestinal metaplasia in the esophageal mucosa. This condition is associated with an increased risk of esophageal adenocarcinoma. BE develops from chronic insult to the esophageal mucosa due to gastroesophageal reflux disease (GERD). Its diagnosis requires endoscopy with multiple biopsies. Numerous image-enhanced modalities have been developed to improve the endoscopic diagnosis of BE and dysplasia. Surveillance has a central role to monitor for progression of metaplastic to dysplastic mucosa and early diagnosis of invasive carcinoma. Whereas nondysplastic BE can benefit from medical or surgical treatment of GERD, today multiple therapies are available to treat dysplastic BE with a low rate of complications. Key words: Barrett esophagus, biopsy, dysplasia endoscopy, endoscopic mucosal resection, esophageal adenocarcinoma, gastroesophageal reflux metaplasia, proton pump inhibitor, surveillance
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
